Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access.
Covered in this story
Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- TD Cowen: $117 → $135 by Aug 2027 · Buy via Investing.com India
- UBS: $107 → $125 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 50 stories mentioning Abbott Laboratories, the earliest published 23 May 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.